eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting
SAN DIEGO, March 18, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced the preclinical profile of lead product candidate eFT508 will be presented at a special drug development track session titled “New Drugs on the Horizon 2” at the Annual Meeting of the American Association for Cancer Research, to be held April 16-20, 2016 in New Orleans at the Ernest N. Morial Convention Center.The presentation, titled “eFT508: An oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2, a novel approach for the treatment of cancer,” will be presented by Kevin Webster, Ph.D., senior vice president, cancer biology, eFFECTOR Therapeutics at 4:15 p.m. CT, on Sunday, April 17, 2016, in New Orleans Theater C, Morial Convention Center.
Separately, in an educational session titled “From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 1– Optimizing Drug Discovery: Insights on an Important Process,” Siegfried Reich, Ph.D., senior vice president, research, eFFECTOR Therapeutics, will present the story of the discovery of lead candidate eFT508 in a presentation titled “Leveraging iterative 3D-structure information while managing physicochemical properties, Design of eFT508: An oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2.” The educational session will run from 8:00 a.m. – 10:00 a.m. CT on Saturday, April 16, 2016, in room 271, Morial Convention Center.
Additionally, in a major symposium entitled “Oncogenic mRNA Translation,” company founder Davide Ruggero, Ph.D., Helen Diller Family Chair in Basic Cancer Research, University of California, San Francisco, will broadly discuss the important role of translation control in cancer in a presentation titled “Translation makes an impact: Tailor-made protein expression for metabolism, cancer & disease” at 11:40 a.m. on Tuesday, April 19, in room 265, Morial Convention Center.
Heidi Chokeir, Ph.D.